Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion. | Harbour BioMed is setting sail as the Solstice begins, ...

Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 ...

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells. Blocking CTLA-4 with a specific antibody is an ...

Development of a novel granulocyte scoring system for use as a predictive/prognostic biomarker in patients with advanced melanoma undergoing treatment with combination immunotherapy. This is an ASCO ...

A fault in cells that form a key part of the immune system can be repaired with a pioneering gene editing technique, finds new research demonstrated in human cells and mice, led by UCL scientists.

Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: A case-control study with translational correlates. Predictive factors for cardiac events following concurrent ...

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and ...

Immune checkpoint inhibitors (ICIs), such as anti-CTLA-4 antibodies, are widely used in cancer immunotherapy. CTLA-4 blockers such as Yervoy (ipilimumab, Bristol Myers Squibb Co.) stimulate ...

SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...